<?xml version='1.0' encoding='utf-8'?>
<document id="26629047"><sentence text="Inhibitory effect of salvianolate on human cytochrome P450 3A4 in vitro involving a noncompetitive manner."><entity charOffset="21-33" id="DDI-PubMed.26629047.s1.e0" text="salvianolate" /></sentence><sentence text="Salvianolic acid B (Sal B), which is purified from Danshen, is a popular herb extract"><entity charOffset="0-18" id="DDI-PubMed.26629047.s2.e0" text="Salvianolic acid B" /><entity charOffset="51-58" id="DDI-PubMed.26629047.s2.e1" text="Danshen" /><pair ddi="false" e1="DDI-PubMed.26629047.s2.e0" e2="DDI-PubMed.26629047.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26629047.s2.e0" e2="DDI-PubMed.26629047.s2.e1" /></sentence><sentence text=" Sal B has anti-oxidative, anti-inflammatory, anti-hypoxic, anti-arteriosclerotic and anti-apoptotic properties" /><sentence text=" This substance can also ameliorate brain injury or neurodegenerative diseases" /><sentence text=" The listed drug Salvianolate, which contains a substantial amount of Sal B, has been used for the treatment of coronary heart disease"><entity charOffset="17-29" id="DDI-PubMed.26629047.s5.e0" text="Salvianolate" /></sentence><sentence text=" Our present work aimed to evaluate the inhibitory effect of salvianolate on seven cytochrome P450 isoforms (CYP450), namely, CYP1A2, CYP2A6, CYP2E1, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, in human liver microsomes (HLMs) and recombinant enzymes through high-performance liquid chromatography (HPLC) assay"><entity charOffset="61-73" id="DDI-PubMed.26629047.s6.e0" text="salvianolate" /></sentence><sentence text=" Salvianolate have a potent inhibitory effect on CYP3A4 activity with IC50 values of 1"><entity charOffset="1-13" id="DDI-PubMed.26629047.s7.e0" text="Salvianolate" /></sentence><sentence text="438 (HLMs) and 3" /><sentence text="582 (recombinant cDNA-expressed CYP3A4) mg/L, respectively" /><sentence text=" Salvianolate strongly dose, but not time-dependently decreased CYP3A4 activity in HLMs"><entity charOffset="1-13" id="DDI-PubMed.26629047.s10.e0" text="Salvianolate" /></sentence><sentence text=" The typical Lineweaver-Burk plots showed that Salvianolate inhibited CYP3A4 activity noncompetitively, with a Ki value of 2"><entity charOffset="47-59" id="DDI-PubMed.26629047.s11.e0" text="Salvianolate" /></sentence><sentence text="27 mg/L in HLMs" /><sentence text=" Other CYP450 isoforms are not markedly affected by Salvianolate"><entity charOffset="52-64" id="DDI-PubMed.26629047.s13.e0" text="Salvianolate" /></sentence><sentence text=" These findings indicate that salvianolate may be involved in potential drug interactions when co-administrated with CYP3A4 substrates"><entity charOffset="30-42" id="DDI-PubMed.26629047.s14.e0" text="salvianolate" /></sentence><sentence text=" " /></document>